Acute toxicity of combined photon IMRT and carbon ion boost for intermediate-risk prostate cancer – Acute toxicity of 12C for PC

Figures & data

Table I. Patient characteristics.

Nr.	T-Stage	GS	Initial PSA [ng/ml]	Age at the start of RT	Hormonal therapy (HT)	Duration of adjuvant HT in month
1	T1c	8 (4−4)	14	67	Bicalutamid	8
2	T3	9 (4 + 5)	14.9	72	Leuprorelinacetat	12
3	T2b	7 (3 + 4)	11	71	Flutamid	6
4	T1c	7 (3 + 4)	10.9	59	-------------	--
5	T2a	7 (3 + 4)	16.94	66	Bicalutamid	6
6	T2a	7 (3 + 4)	13.78	69	Bicalutamid	12
7	T2c	8 (4 + 4)	17.2	70	Bicalutamid	6
8	T2b	8 (4 + 4)	12.4	57	Bicalutamid	42
9	T1c	7 (4 + 3)	12.9	73	--------------	--
10	T2b	8 (4 + 4)	11	75	Bicalutamid	9
11	T2a	7 (3 + 4)	17.2	72	Goserelin	12
12	T2c	7 (4 + 3)	10.7	55	Bicalutamid	12
13	T1c	7 (3 + 4)	10.8	69	Goserelin	12
14	T2a	7 (3 + 4)	11	73	Goserelin	24

Table II. Detailed data of acute toxicity.

Nr.	GU/grade	GI/grade
1	0	0
2	1 (nocturia 1-2)	0
3	2 (nocturia 3-4, pollacisuria)	1 (rectal tenesmus)
4	2 (nocturia 3-4, dysuria)	0
5	2 (nocturia 3-4, dysuria)	0
6	1 (nocturia 1-2)	1 (rectal tenesmus)
7	1 (nocturia 1-2)	0
8	1 (nocturia 1-2)	0
9	1 (nocturia 1-2)	1 (rectal tenesmus)
10	1 (nocturia 1-2)	1 (acute anal bleeding with moderate pain)
11	1 (nocturia 1-2)	0
12	2 (nocturia 3-4, dysuria)	0
13	0	1 (acute anal bleeding with moderate pain, obstipation)
14	2 (nocturia 5-6)	0

Figure 1. PSA development in study patients.

Figure 2. Actuarial biochemical relapse free survival (Kaplan-Meier curve).